CryoTherapeutics GmbH closes a B round financing to advance clinical trials and establish operations in Belgium, focusing on innovative cryotherapy treatments for coronary artery disease.

Target Information

CryoTherapeutics GmbH, along with its subsidiary CryoTherapeutics SA, is a medical technology company that specializes in the development of cryotherapy systems aimed at treating coronary artery disease. Founded in December 2009, the company has emerged as a pioneer in utilizing cryo-energy to stabilize inflamed areas of the coronary artery, thereby reducing the risk of heart attacks. With a proprietary intravascular catheter capable of delivering sub-zero temperatures directly to affected areas, CryoTherapeutics seeks to demonstrate clinical benefit and pursue early-stage commercialization of its innovative technology.

The company’s recent B round financing marks a significant milestone, as it provides essential capital to support their clinical trials program, enhance research and development efforts, and establish operations in Awans, Belgium. This strategic investment aligns with the company’s goal of advancing the capabilities of interventional cardiologists in treating atherosclerotic diseases.

Industry Overview in Belgium

Belgium has a robust medical technology sector, characterized by a strong support network for innovation and investment. The country has made significant strides in healthtech over the past few years, attracting both local and international investors. A favorable